ClinicalTrials.gg
CompletedNCT07254871BASITUpdated Aug 31, 2026

Study of DM-101PX in Adults With Birch Pollen Allergy

A Phase 2 interventional study of DM-101PX and Placebo in Birch Pollen Allergy, sponsored by Desentum Oy. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Desentum Oy · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada — 2 open to participants now, 3 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Canada.

Enrollment
18th of 32
97 · median 104
Started
2025
with 1 other
Phase 2
18 of 33
1 open now
Registered
31st of 33
by date
Lead sponsor
2 of 33
Desentum Oy

Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2025, is one of 18 in phase 2, and was the 31st registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

2 of the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, or all of them as a file.
02

Study summary

Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults. Expanded access to the study treatment is not available.

Read the detailed description

The study will be carried out in two study sites located in Canada

03

Conditions studied

  • Birch Pollen Allergy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant of either sex and any race, aged 18 to 65 years inclusive.
  • Documented clinical history of birch pollen-induced allergic rhinitis or rhinoconjunctivitis with symptoms that interfere with daily activities or sleep and remain bothersome despite the use of relevant symptomatic medication, and have been present over, at least, 2 previous allergy seasons.
  • Bet v 1 specific serum IgE ≥ 0.7 kAU/L.
  • Positive Skin Prick Test to birch pollen allergen, with a wheal diameter ≥ 5 mm.
  • Body weight ≥ 50 kg and (BMI) within the range 18-35 kg/m2 inclusive.

Exclusion criteria

Exclusion Criteria:

  • History or findings on physical examination at screening visit of any significant disease or disorder which, in the opinion of the Investigator, could put the participant at risk because of participation in the study, influence the results of the study or the participant's ability to participate in the study.
  • History of significant rhinitis, sinusitis, and/or presence of significant symptoms of respiratory allergy due to regular contact with other allergens, not associated with the birch pollen season, that are expected to coincide or potentially interfere with the study allergen challenge assessments, as assessed by the Investigator.
  • History of nasal polyps or other nasal oropharyngeal conditions that in the judgement of the Investigator may interfere with study outcome assessments.
  • History of requiring regular treatment.
  • Current diagnosis of uncontrolled, partially controlled or persistent asthma requiring regular (> 6 weeks per year) maintenance use of inhaled . History of severe asthma during the pollen season. History of asthma deterioration that resulted in emergency treatment or hospitalization in the 12 months before screening, or a life-threatening asthma attack at any time in the past.
  • (FEV1) \< 75% of predicted. History of severe drug allergy, severe angioedema or systemic allergic reaction of Grade 3 or greater, according to the World Allergy Organization (WAO) scale, due to any cause.
  • History of intolerance to the Product, rescue medications used for systemic allergic reactions (i.e., adrenaline, antihistamine, glucocorticoids, and beta-2 agonists such as salbutamol), or their .
  • History of acute and/or anaphylaxis to protein therapeutics or components of formulation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    DM-101PX

    weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks

    Biological: DM-101PX

  • Placebo comparator
    Placebo

    weekly subcutaneous administration of Placebo for 10 weeks

    Biological: Placebo

Interventions

  • BiologicalDM-101PX

    subcutaneous injection of DM-101PX

  • BiologicalPlacebo

    Placebo to match DM-101PX administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Change in Total Nasal Symptom Score (TNSS) after treatment

    Change in AUC for TNSS from baseline to post-treatment visit. TNSS is a symptom score consisting of 4 nasal symptoms, each symptom is rated as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). TNSS score can very between 0-12.

    Time frame: From baseline to 3 weeks after the last dose

Secondary outcomes

  1. Adverse events (AEs)

    Incidence and characteristics of AEs from the start of treatment to the post-treatment NAC visit.

    Time frame: from the start of treatment to 3 weeks after the last dose

  2. Laboratory safety evaluations

    Number and percentage of participants with new onsets of clinically significant abnormalities (as assessed by the investigator) in laboratory safety evaluations

    Time frame: from the start of treatment to 3 weeks after the last dose

  3. Vital signs

    Number and percentage of participants with new onsets of clinically significant abnormalities (as assessed by the investigator) in vital signs

    Time frame: From the start of treatment to 3 weeks after the last dose

  4. Adverse Events of Special Interest (AESIs)

    Incidence and characteristics AESIs: local injection site reactions and systemic allergic reactions

    Time frame: From the start of treatment to 3 weeks after the last dose

  5. Change in TNSS after follow-up period

    Change in AUC for TNSS from baseline to follow-up visit.

    Time frame: from baseline to 20-30 weeks after the last dose

  6. Change in Total Symptom Score (TSS)

    Change in AUC for TSS from baseline to 1) post-treatment, 2) follow-up visit

    Time frame: From baseline to 1) 3 weeks, 2) 20-30 weeks after the last dose

  7. Change in Peak Nasal Inspiratory Flow (PNIF)

    Change in AUC for PNIF from baseline to 1) post-treatment visit, 2) follow-up visit

    Time frame: from baseline to 1) 3 weeks, 2) 20-30 weeks after the last dose

  8. Change in blood allergy biomarker levels

    Change from baseline to the 7th injection, the 10th injection, post-treatment and follow-up visit in the levels of Bet v 1-specific IgE, IgG1 and IgG4.

    Time frame: From baseline to the 7th injection, the 10th injection, 3 weeks after the last dose, and 20-30 weeks after the last dose.

07

Study locations

1 site
  • Cliantha Research
    Mississauga, Ontario ON L4W 1A4, Canada
08

References and documents

Individual participant data

Plan to share: Yes — All individual participant data that underlie publicly available results will be considered for sharing Anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant reidentification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Anonymized participant data will be considered for sharing once the product and indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant reidentification.

Access criteria: Qualified researchers may request access to patient level data and related study documents: patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants after Desentum has received marketing authorization from major health authorities (e.g. FDA, EMA), has the legal authority to share the data, and has made the study results publicly available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Apr 2026, 6 months.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 6 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Nov 28, 2025
StartActual
Sep 26, 2025
Primary completionActual
Apr 15, 2026
CompletionActual
Aug 10, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07254871
Lead sponsor
Desentum Oy
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Sep 26, 2025
Primary completion
Apr 15, 2026
Completion
Aug 10, 2026
Last update
Aug 31, 2026

Study contacts

Dirk-Jan Opstelten, PhD
study director · Desentum Oy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM-101PX

Start the discussion